In contrast to anti-PD-1 therapy, which blocks T-cell inhibition and reactivates T-cells, MET inhibitors act by inhibiting IFN-γ-induced JAK–STAT signaling and its downstream PD-L1 expression in human melanoma cells. The gene discussed is SOAT1; the disease is melanoma.